Working… Menu

TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01108042
Recruitment Status : Completed
First Posted : April 21, 2010
Last Update Posted : May 18, 2016
Information provided by (Responsible Party):
Orlando Guntinas-Lichius, Prof. Dr. med., University of Jena

Brief Summary:

A combination therapy of Docetaxel, Cisplatin und 5-Fluorouracil (= TPF) will be used in patients with resectable oropharyngeal and cavity of the mouth cancer. To improve the compatibility of the TPF-induction without decreasing the efficacy the dose will be given on day 1 and 8 instead of applying the whole dose on day 1 every 3 weeks.

In the phase I-part of the trial the optimal therapeutic dose of Docetaxel and Cisplatin will be defined.

In the phase II-part the progression-free survival after 2 years will be assessed in patients treated with the optimal therapeutic dose.

Condition or disease Intervention/treatment Phase
Oropharynx Cancer Squamous Cell Carcinoma of the Oral Cavity Drug: Taxotere, Cisplatin, 5-Fluorouracil (5-FU) Phase 1 Phase 2

Detailed Description:

Local advanced Oropharyngeal and cavity of the mouth Cancer are often treated with a combination of surgery and/or radiation and /or chemotherapy.

Despite of therapy improvement there are only little advances in progression-free survival and overall survival.

Therefore new therapy concepts are needed. The advantage of the induction chemotherapy is the possibility of tumor response assessment during chemotherapy and may present a selection criterion for organ preservation.

In order to minimize the time between chemotherapy and surgery it is important to have an early answer for the tumor response. In this study response will be assessed after the first cycle of chemotherapy. Patients showing no tumor response will be operated at once. The other patients will receive further cycles of chemotherapy.

Toxicity of the induction chemotherapy have to be moderate because surgery should not be delayed.

To improve the tolerance of induction therapy the medication dose isn't given on day 1 every 3 weeks, but is dispersed on day 1 and day 8, q3weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 71 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Study of Split-dose TPF-Induction Chemotherapy Before Surgery of Oropharyngeal and Cavity of the Mouth Cancer
Study Start Date : November 2009
Actual Primary Completion Date : January 2016
Actual Study Completion Date : February 2016

Arm Intervention/treatment
Experimental: Taxotere, Cisplatin, 5-Fluorouracil (5-FU)
Phase 1: Intravenous infusion of 40 mg/m² Taxotere and 40 mg/m² Cisplatin followed by 24 h-infusion of 2000 mg/m² 5-FU on day 1 and day 8 every 3 weeks. If possible an escalation to 50 mg/m² Taxotere and 50 mg/m² Cisplatin can be carried out.
Drug: Taxotere, Cisplatin, 5-Fluorouracil (5-FU)
Phase 1: Intravenous infusion of 40 mg/m² Taxotere and 40 mg/m² Cisplatin followed by 24 h-infusion of 2000 mg/m² 5-FU on day 1 and day 8 every 3 weeks. If possible an escalation to 50 mg/m² Taxotere and 50 mg/m² Cisplatin can be carried out. Phase 2: Optimal dose of phase 1 will be given.
Other Name: Docetaxel

Primary Outcome Measures :
  1. Determination of progression-free survival after 2 years [ Time Frame: 24 months ]

Secondary Outcome Measures :
  1. Overall survival after 2 years [ Time Frame: after 2 years ]
  2. Determination of the efficacy of the induction therapy [ Time Frame: after 1, 12 and 24 months ]
    CT or magnetic resonance tomography (MRT) of the neck region

  3. Function of swallowing according the penetration-aspiration-scale [ Time Frame: 0,1, 6, 12, 18, 24 months ]
    assessed according the penetration-aspiration-scale (PAS, Rosenbek et al. 1996) and according measuring after Prosiegel (Prosiegel et al. 2002).

  4. Adverse events as a measure of safety and tolerability [ Time Frame: once a week ]
    The number of patients with adverse events will be evaluated. Adverse events will be assessed according Common Terminology Criteria of Adverse Events (CTCAE) v.3.0 and analysed as number per patient and number per cycle.

  5. Quality of life [ Time Frame: 0,1, 6, 12, 18, 24 months ]
    European Organisation for Research and Treatment of Cancer (EORTC) Quality of life questionnaire (QLQ) for head and neck cancer patients (HN35) questionnaire filled in by the patients

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histological proven, resectable squamous epithelial carcinoma of the oropharynx and the cavity of the mouth
  2. R0-resection possible
  3. All T N2 M0 / all T N3 M0 / if T3 or T4a also N0-1 M0
  4. Leucocytes > 4000/mm³ bzw. neutrophils > 2000/mm³, thrombocytes > 100000/mm³
  5. adequate kidney function, defined as serum creatinine und urea in normal range, Creatinine clearance > 60 ml/min
  6. adequate liver function with glutamate oxaloacetate transaminase (SGOT), glutamate pyruvate transaminase (SGPT) and bilirubin in normal range
  7. electrolytes in normal range
  8. risks of anesthesia complications normal or minor increased
  9. Eastern Cooperative Oncology Group (ECOG) 0-2 / Karnofsky >= 60%
  10. Age 18 - 80 years
  11. signed written informed consent
  12. effective contraception for both male and female subjects if the risk of conception exists

    Exclusion Criteria:

  13. T1 N0 M0 / T1 N1 M0 / T2 N0 M0 / T2 N1 M0
  14. Resection without curative intention: primary tumor is not treatable with resection methods
  15. Infiltration of the lower jaw
  16. M1 status
  17. Tumor not measurable with Innovation Center Computer Assisted Surgery (ICCAS) methods
  18. No prior chemotherapy or radiation (a primary surgery is allowed)
  19. Metachronous or oder synchronous malignoma (Exception: basal cell carcinoma)
  20. Life expectance < 3 months
  21. ECOG > 2; Karnofsky < 60%
  22. acute infections or fever
  23. known HIV-infection or other immune suppression
  24. severe cardio pulmonary concomitant diseases
  25. chronic disease with continuous therapy (uncontrolled diabetes, rheumatoid arthritis) especially continuous therapy with steroids
  26. other concomitant diseases which, in the investigator's opinion, would exclude the patient from the study
  27. Contraindications which permit a therapy with Docetaxel, Cisplatin, 5-FU or radiation therapy
  28. missing patient's compliance
  29. regular Follow-up visits not possible
  30. Pregnancy or lactation period
  31. legal incapacity or limited legal capacity
  32. Participation in another clinical trial or administration of a not approved substance within 30 days before registration

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01108042

Layout table for location information
Städt. Kliniken Bielefeld gem. GmbH
Bielefeld, Germany, 33604
Friedrich-Schiller-University Jena
Jena, Germany, 07740
Universitätsklinikum Leipzig - Klinik und Poliklinik für HNO-Heilkunde
Leipzig, Germany, 04103
Klinikum Ernst von Bergmann
Potsdam, Germany, 14467
Sponsors and Collaborators
Orlando Guntinas-Lichius, Prof. Dr. med.
Layout table for investigator information
Principal Investigator: Orlando Guntinas-Lichius, Prof. Dr. Friedrich-Schiller-University Jena
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Orlando Guntinas-Lichius, Prof. Dr. med., Professor Dr. med., University of Jena Identifier: NCT01108042    
Other Study ID Numbers: TISOC-1
2009-011902-41 ( EudraCT Number )
First Posted: April 21, 2010    Key Record Dates
Last Update Posted: May 18, 2016
Last Verified: May 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Oropharyngeal Neoplasms
Mouth Neoplasms
Pharyngeal Neoplasms
Otorhinolaryngologic Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Pharyngeal Diseases
Stomatognathic Diseases
Otorhinolaryngologic Diseases
Mouth Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs